EBMT 2019 | T-cell depleted haploidentical SCT followed by ATIR101 vs. T-cell replete HSCT plus chemo
Denis-Claude Roy
• 24 Mar 2019
Denis-Claude Roy, MD, FRCPC, from the University of Montreal, Montreal, Canada, discusses a Phase III trial of haploidentical transplant with a T-cell depleted stem cell graft repleted with anti-leukemia and anti-viral allogeneic T-cells vs. a T-cell replete transplant followed by cyclophosphamide (NCT02999854). This interview took place at the European Society for Blood and Marrow Transplantation (EBMT) 2019 Annual Meeting, held in Frankfurt, Germany.
